Venture Capital Archives - Page 110 of 113 - Boston Life Sciences Times

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

July 17, 2026

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

July 16, 2026

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

July 15, 2026

THIS WEEK'S STORIES

Draig Therapeutics Raises $65 Million to Advance Neuropsychiatric Drug Pipeline

July 14, 2026

Ironwood Names Jeffrey Silber Chief Medical Officer as Phase 3 STARS-2 Trial Begins Recruiting

July 14, 2026

Cellares and Sonoma Biotherapeutics Partner to Automate Treg Cell Therapy Manufacturing

July 13, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Venture Capital

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

Draig Therapeutics Raises $65 Million to Advance Neuropsychiatric Drug Pipeline

Pediatrica Health Group Raises $28 Million to Expand Pediatric Primary Care

Novartis to Acquire Sofinnova-Backed Myricx Bio in Deal Worth Up to $1.5 Billion

Anodyne Nanotech Raises $12.6 Million to Advance Weekly GLP-1 Patch

Most Read

Mirador Therapeutics Licenses Long-Acting Anti-C5a Antibody from Kira Pharmaceuticals

Bayer and Henry Ford Health Partner to Expand Patient Access to Clinical Trials

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Aqemia and Sanofi Expand AI-Driven Drug Discovery Collaboration

EDITOR PICKS

Inflammasome Therapeutics Reports Positive Phase 2 Results for K8 in Geographic Atrophy

Syntis Bio Reports Positive Initial Phase 1/1b Data for Obesity Drug SYNT-101

AdvanCell Raises $315 Million to Advance Targeted Alpha Cancer Therapies

THIS WEEK'S STORIES

Draig Therapeutics Raises $65 Million to Advance Neuropsychiatric Drug Pipeline

Ironwood Names Jeffrey Silber Chief Medical Officer as Phase 3 STARS-2 Trial Begins Recruiting

Cellares and Sonoma Biotherapeutics Partner to Automate Treg Cell Therapy Manufacturing

POPULAR CATEGORY

ABOUT US

FOLLOW US